Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.67 |
| ▸ | MAOB | P27338 | 6/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9372702 | 0.95 | MRGPRX4 (0.70) | MRGPRX4MAOBLOXL2ADAMTS4MMP13 | |
| SCHEMBL10411878 | 0.89 | MRGPRX4 (0.77) | MRGPRX4MAOBNR4A2MAOACYSLTR1 | |
| SCHEMBL1122805 | 0.88 | MRGPRX4 (0.71) | MRGPRX4MAOBNR4A2CYSLTR1SMPD1 | |
| SCHEMBL6174966 | 0.86 | SMN1; SMN2 (0.59) | LOXL2 | |
| SCHEMBL9372701 | 0.86 | MRGPRX4 (0.69) | MRGPRX4MAOBLOXL2ADAMTS4MMP13 | |
| SCHEMBL2654709 | 0.85 | MRGPRX4 (0.71) | MRGPRX4MAOBNR4A2MAOACYSLTR1 | |
| SCHEMBL30412034 | 0.85 | MAOB (0.73) | MRGPRX4MAOBNR4A2CYSLTR1SMPD1 | |
| SCHEMBL976424 | 0.85 | MAOB (0.73) | MRGPRX4MAOBNR4A2CYSLTR1SMPD1 | |
| SCHEMBL10659025 | 0.84 | MRGPRX4 (0.74) | MRGPRX4MAOBMAOA | |
| SCHEMBL7719391 | 0.84 | MRGPRX4 (0.70) | MRGPRX4MAOBNR4A2MAOACYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062351-A1 | Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| EP-1697325-A1 | BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES USEFUL AS GLUCOKINASE (GLK) ACTIVATORS | AstraZeneca AB (SE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005056530-A1 | BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES USEFUL AS GLUCOKINASE (GLK) ACTIVATORS | ASTRAZENECA AB (SE) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062351-A1 | Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators | GCK, GCKR, GALK1 | MRGPRX4 928/4885MAOB 713/4885NR4A2 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.